丰原药业 2024 年度股东大会 法律意见书 安徽径桥律师事务所 关于安徽丰原药业股份有限公司 2024 年度股东大会法律意见书 本次股东大会现场会议于 2025 年 5 月 6 日下午 14:30 如期在合肥市包河区大连 路 16 号公司总部办公楼四楼第一会议室召开。 1 遵照《中华人民共和国公司法》（以下简称《公司法》）、《上市公司股东大会规 则》（以下简称《股东大会规则》）、《关于加强社会公众股股东权益保护的若干规定》 （以下简称《若干规定》）等法律、法规及《安徽丰原药业股份有限公司章程》（以 下简称《公司章程》）的有关规定，安徽径桥律师事务所（以下简称本所）接受安徽 丰原药业股份有限公司（以下简称公司）的专项委托，指派常合兵、洪锦律师出席 公司 2024 年度股东大会（以下简称本次股东大会），并就公司本次股东大会的召集、 召开程序、出席会议人员资格、股东大会的表决程序等相关问题出具法律意见。 本所仅依据法律意见书出具日前已经发生或存在的事实及本所律师对我国法律、 法规的理解发表法律意见。 为出具本法律意见书，本所律师审查了公司提供的与本次股东大会有关的文件。 经本所律师核对，这些文件中的副本或复印件， ...

股票简称：丰原药业 股票代码：000153 公告编号：2025-020 安徽丰原药业股份有限公司 2024 年度股东大会决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性陈述 或者重大遗漏。 重要内容提示： 1、本次股东大会无增加、变更、否决提案的情况。 2、本次股东大会未涉及变更前次股东大会决议的情形。 一、会议召开和出席情况 （一）会议召开情况 1、会议召开时间： （1）现场会议召开时间：2025 年 5 月 6 日下午 14:30。 （2）网络投票时间：2025 年 5 月 6 日；其中，通过深圳证券交易所交易系统进 行网络投票时间为：2025 年 5 月 6 日上午 9:15-9:25、9:30-11:30，下午 13:00-15:00； 通过互联网投票系统投票时间为：2025 年 5 月 6 日 9:15-15:00。 2、现场会议召开地点：合肥市包河区大连路 16 号公司总部办公楼四楼第一会 议室。 3、会议方式：本次股东大会采取现场投票与网络投票相结合的表决方式。 4、召集人：公司第九届董事会。 5、现场会议主持人：公司董事长何宏满先生。 6、本次股东大会的召集 ...

Group 1: Company Growth Strategies - The company aims to enhance efficiency through lean management to reduce costs and increase effectiveness [1] - Accelerating new product development to improve innovation capabilities and competitiveness is a key focus for 2025 [1] - Strengthening partnerships to leverage the company's extensive product pipeline and production capacity for new growth opportunities [1] Group 2: Revenue Composition - In 2024, the revenue composition is as follows: Chemical preparations approximately 30%, chemical raw materials about 10%, and traditional Chinese medicine less than 1% [2] - The company plans to increase the development of classic traditional Chinese medicine products to enrich its product pipeline [1] Group 3: Financial Performance - The company achieved its highest historical revenue and net profit attributable to shareholders in 2024 [2] - R&D expenses for 2024 are approximately 63 million, primarily focused on high-end generic drugs [3] Group 4: Market Challenges and Responses - The company continues to maintain a certain market share for core products despite the impact of centralized procurement policies [2] - Measures to stabilize the gross profit margin of core products include cost reduction and efficiency improvement [2] Group 5: Stock Performance and Future Plans - The company acknowledges the uncertainty affecting stock prices due to market conditions and operational performance [3] - Plans to enhance profitability include optimizing store layouts and developing online business [3] Group 6: Environmental and Social Responsibility - The company emphasizes environmental protection and energy conservation, implementing projects like boiler upgrades and direct power supply to meet national environmental goals [4]

本议案已经公司董事会审计委员会审议通过。 同意票 9 票，无反对和弃权票。 二、通过《关于对全资子公司流动资金贷款提供担保的议案》 为扩大子公司经营的需要，公司对全资子公司提供如下担保： 1、公司董事会同意公司对全资子公司安徽泰服医药有限公司两年期限内（自公 司与招商银行合肥分行签订最高额保证合同之日起）在招商银行合肥分行办理的不 超过 5,000 万元的信贷业务提供担保。 股票简称：丰原药业 股票代码：000153 公告编号：2025-017 安徽丰原药业股份有限公司 第九届二十三次董事会决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性陈述或 者重大遗漏。 安徽丰原药业股份有限公司（下称"公司"）第九届二十三次董事会会议于 2025 年 4 月 23 日在公司办公楼第一会议室召开。本次会议通知于 2025 年 4 月 13 日以送 达或电子邮件等方式向公司全体董事、监事及其他高级管理人员发出。在保障所有 董事充分表达意见的情况下，本次会议采用现场和通讯方式进行表决，应参加表决 的董事 9 人，实际参加表决 9 人，其中公司董事陆震虹女士以通讯方式表决。公司 监事和其他高管 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥940,757,024.36, representing a decrease of 16.05% compared to ¥1,120,669,012.93 in the same period last year[4] - Net profit attributable to shareholders was ¥38,020,772.30, down 19.12% from ¥47,010,852.21 year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥33,527,334.75, a decline of 19.55% compared to ¥41,674,569.58 in the previous year[4] - Basic earnings per share decreased to ¥0.0818, down 19.09% from ¥0.1416 year-on-year[4] - Net profit for the current period was ¥37,327,699.99, down 19% from ¥46,363,541.16 in the previous period[17] - Earnings per share (basic and diluted) decreased to ¥0.0818 from ¥0.1011, representing a decline of 19%[18] Cash Flow - Cash flow from operating activities was ¥12,332,315.23, down 21.84% from ¥15,777,633.43 in the same period last year[4] - Cash inflow from operating activities totaled ¥804,991,564.53, down from ¥977,470,684.37, indicating a decrease of about 18%[19] - The net cash flow from operating activities was $12,332,315.23, a decrease of 21.5% compared to $15,777,633.43 in the previous period[20] - Cash outflow from operating activities totaled $792,659,249.30, down from $961,693,050.94, indicating a reduction of 17.6%[20] - The ending cash and cash equivalents balance was $222,278,551.39, down from $273,739,417.10, reflecting a decrease of 18.8%[20] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,795,953,473.63, an increase of 2.06% from ¥4,698,947,415.21 at the end of the previous year[4] - Total current assets amount to ¥2,022,355,332.44, an increase from ¥1,965,350,782.21 at the beginning of the period[13] - Accounts receivable increased to ¥1,015,724,048.79 from ¥934,569,467.81, reflecting a growth of approximately 8.5%[13] - Total liabilities rose to ¥2,706,273,260.32 from ¥2,653,036,981.33, reflecting an increase of about 2%[15] - The equity attributable to shareholders of the parent company increased to ¥2,063,980,530.84 from ¥2,019,573,061.58, a growth of approximately 2%[15] Research and Development - The company's R&D expenses increased by 32.77% to ¥17,238,043.80, compared to ¥12,983,646.70 in the previous year, indicating a focus on innovation[8] - Research and development expenses increased to ¥17,238,043.80 from ¥12,983,646.70, representing a rise of about 33%[17] Shareholder Information - Total number of common shareholders at the end of the reporting period is 35,431[10] - The largest shareholder, Anhui Wuwei Pharmaceutical Factory, holds 10.80% of shares, totaling 50,178,992 shares[10] - The company reported a total of 10 major shareholders, with the top four holding a combined 28.62% of shares[10] Operating Costs and Expenses - Total operating costs decreased to ¥900,028,700.48 from ¥1,058,729,460.12, reflecting a reduction of approximately 15%[17] - The company reported a decrease in sales expenses by 38.80% to ¥97,653,829.08, attributed to reduced market expansion costs due to lower revenue[8] Government Subsidies - Government subsidies recognized during the period amounted to ¥10,544,434.21, a decrease of 43.81% from the previous year[8] Cash Flow from Financing Activities - Cash inflow from financing activities amounted to $328,585,943.07, an increase from $254,899,033.63, representing a growth of 28.9%[20] - The net cash flow from financing activities was $83,758,822.52, slightly up from $81,911,173.50, indicating a growth of 2.3%[20] Other Financial Metrics - Other comprehensive income after tax for the current period was ¥5,223,904.42, compared to a loss of ¥92,681.15 in the previous period[18] - Cash outflow for the acquisition of fixed assets and other long-term assets was $91,534,251.72, significantly higher than $29,711,320.33, marking an increase of 208.5%[20] - The company received $328,585,943.07 in cash from borrowings, up from $252,899,033.63, which is an increase of 29.9%[20] - The cash paid for employee compensation was $123,655,072.29, compared to $124,532,719.85, showing a slight decrease of 0.7%[20] - The cash paid for taxes was $56,419,902.11, down from $69,459,120.30, indicating a decrease of 18.8%[20]

股票简称：丰原药业 股票代码：000153 公告编号：2025-019 安徽丰原药业股份有限公司关于 对全资子公司流动资金贷款提供担保的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性陈述或者 重大遗漏。 一、 担保情况概述 2025 年 4 月 23 日，公司召开第九届董事会第二十三次会议，以 9 票同意、无反对 和弃权票，审议通过《关于对全资子公司流动资金贷款提供担保的议案》。 1、公司董事会同意公司对全资子公司安徽泰服医药有限公司两年期限内（自公司 与招商银行合肥分行签订最高额保证合同之日起）在招商银行合肥分行办理的不超过 5,000 万元的信贷业务提供担保。 2、公司董事会同意公司对全资子公司安徽泰服医药有限公司两年期间内（自公司 与华夏银行合肥高新区支行签订最高额保证合同之日起）在华夏银行合肥高新区支行 办理的不超过 3,000 万元的信贷业务提供担保。 根据深交所《股票上市规则》及本公司章程的相关规定，公司本次对外担保事项 无需公司股东大会批准。 二、被担保人基本情况 6、主要财务指标: 7、被担保方安徽泰服医药有限公司不是失信被执行人。 安徽泰服医药有限公司 1、 ...

Market Overview - The Shanghai Composite Index closed at 3299.76 points, above the annual line, with a change of 0.25% [1] - The total trading volume of A-shares reached 1,121.207 billion yuan [1] Stocks Breaking Annual Line - A total of 106 A-shares have broken above the annual line today [1] - Notable stocks with significant deviation rates include: - Youbuxun: 17.49% deviation, closing price at 15.18 yuan, with a daily increase of 20.00% and turnover rate of 6.57% [1] - Fujilai: 14.53% deviation, closing price at 29.09 yuan, with a daily increase of 20.01% and turnover rate of 30.40% [1] - Chongqing Construction: 8.33% deviation, closing price at 3.01 yuan, with a daily increase of 9.85% and turnover rate of 2.93% [1] Additional Stocks with Minor Deviations - Jiangxi Copper, Meirya, and Laimu Co. have just crossed the annual line with smaller deviation rates [1] - Other stocks with notable performance include: - Changjiang Investment: 7.98% deviation, closing price at 8.01 yuan, with a daily increase of 10.03% [1] - Qingtang City: 7.70% deviation, closing price at 3.78 yuan, with a daily increase of 9.88% [1] - Shenchuan A: 7.45% deviation, closing price at 6.75 yuan, with a daily increase of 9.93% [1] Summary of Stocks with Deviation Rates - A detailed table lists various stocks, their daily change percentages, turnover rates, annual line prices, latest prices, and deviation rates, highlighting the performance of stocks like: - Dongjiang Environmental: 3.70% deviation, closing price at 4.28 yuan, with a daily increase of 10.03% [1] - Feinan Resources: 3.56% deviation, closing price at 19.88 yuan, with a daily increase of 3.92% [1] - The table provides a comprehensive view of the market dynamics and stock performances on the day [2]

投资者依据提示，授权登入"约调研"小程序，即可参与交流。 出席本次网上说明会的人员有：公司董事长何宏满先生，董事兼总经理汝添乐先 生，独立董事陈结淼先生，董事兼董事会秘书张军先生，财务总监李俊先生。 安徽丰原药业股份有限公司（以下简称"公司"）已于2025年4月11日在巨潮资讯 网（http://www.cninfo.com.cn/）上披露了《公司2024年年度报告》。 为便于广大投资者进一步了解公司2024年度经营情况，公司定于2025年4月24日 （星期四）下午15:00至16:30，在"约调研"小程序上举行2024年度网上业绩说明会。 本次业绩说明会将采用网络远程的方式举行，投资者可登陆"约调研"小程序参与互 动交流。为广泛听取投资者的意见和建议，提前向广大投资者征集问题，提问通道自 发出公告之日起开放。 参与方式一：在微信小程序中搜索"约调研"。 参与方式二：微信扫一扫以下二维码。 证券代码：000153 证券简称：丰原药业 公告编号：2025--016 安徽丰原药业股份有限公司 关于召开2024年度业绩说明会的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，公告不存在虚假记载、误导性陈 述 ...

股票简称：丰原药业 股票代码：000153 公告编号：2025-013 安徽丰原药业股份有限公司 如否，请详细说明：______________________________ 独立董事提名人声明与承诺 提名人安徽丰原药业股份有限公司董事会现就提名张瑞稳为安徽丰原药 业股份有限公司第 10 届董事会独立董事候选人发表公开声明。被提名人已书 面同意作为股份有限公司第 10 届董事会独立董事候选人（参见该独立董事候 选人声明）。本次提名是在充分了解被提名人职业、学历、职称、详细的工作 经历、全部兼职、有无重大失信等不良记录等情况后作出的，本提名人认为被 提名人符合相关法律、行政法规、部门规章、规范性文件和深圳证券交易所业 务规则对独立董事候选人任职资格及独立性的要求，具体声明并承诺如下事项： 一、被提名人已经通过安徽丰原药业股份有限公司第 9 届董事会提名委员 会或者独立董事专门会议资格审查，提名人与被提名人不存在利害关系或者其 他可能影响独立履职情形的密切关系。 是 □ 否 如否，请详细说明：______________________________ 二、被提名人不存在《中华人民共和国公司法》第一百四十六条等 ...